| Nanoparticle-mediated cellular response is size-dependent W Jiang, BYS Kim, JT Rutka, WCW Chan Nature nanotechnology 3 (3), 145-150, 2008 | 3238 | 2008 |
| Nanomedicine BYS Kim, JT Rutka, WCW Chan New England Journal of Medicine 363 (25), 2434-2443, 2010 | 1472 | 2010 |
| Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice S Zhu, IG Stavrovskaya, M Drozda, BYS Kim, V Ona, M Li, S Sarang, ... Nature 417 (6884), 74-78, 2002 | 1315 | 2002 |
| Phagocytosis checkpoints as new targets for cancer immunotherapy M Feng, W Jiang, BYS Kim, CC Zhang, YX Fu, IL Weissman Nature Reviews Cancer 19 (10), 568-586, 2019 | 729 | 2019 |
| Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation Z Yang, J Shi, J Xie, Y Wang, J Sun, T Liu, Y Zhao, X Zhao, X Wang, Y Ma, ... Nature biomedical engineering 4 (1), 69-83, 2020 | 572 | 2020 |
| Improving immune–vascular crosstalk for cancer immunotherapy Y Huang, BYS Kim, CK Chan, SM Hahn, IL Weissman, W Jiang Nature Reviews Immunology 18 (3), 195-203, 2018 | 443 | 2018 |
| Breaking down the barriers to precision cancer nanomedicine C von Roemeling, W Jiang, CK Chan, IL Weissman, BYS Kim Trends in biotechnology 35 (2), 159-171, 2017 | 343 | 2017 |
| Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes Y Qie, H Yuan, CA Von Roemeling, Y Chen, X Liu, KD Shih, JA Knight, ... Scientific reports 6 (1), 26269, 2016 | 297 | 2016 |
| Designing nanomedicine for immuno-oncology KBYS Jiang W, Roemeling C, Chen Y, Qie Y, Liu X, Chen J Nature Biomedical Engineering 1 (1), 29, 2017 | 235* | 2017 |
| Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target N Abdelfattah, P Kumar, C Wang, JS Leu, WF Flynn, R Gao, DS Baskin, ... Nature communications 13 (1), 767, 2022 | 228 | 2022 |
| Increased vessel perfusion predicts the efficacy of immune checkpoint blockade X Zheng, Z Fang, X Liu, S Deng, P Zhou, X Wang, C Zhang, R Yin, H Hu, ... The Journal of clinical investigation 128 (5), 2104-2115, 2018 | 200 | 2018 |
| Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity CA von Roemeling, Y Wang, Y Qie, H Yuan, H Zhao, X Liu, Z Yang, ... Nature communications 11 (1), 1508, 2020 | 198 | 2020 |
| Advances and challenges of nanotechnology-based drug delivery systems W Jiang, BYS Kim, JT Rutka, WCW Chan Expert opinion on drug delivery 4 (6), 621-633, 2007 | 188 | 2007 |
| On the issue of transparency and reproducibility in nanomedicine HS Leong, KS Butler, CJ Brinker, M Azzawi, S Conlan, C Dufès, A Owen, ... Nature nanotechnology 14 (7), 629-635, 2019 | 182 | 2019 |
| Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles W Jiang, Y Huang, Y An, BYS Kim ACS nano 9 (9), 8689-8696, 2015 | 162 | 2015 |
| Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets BYS Kim, W Jiang, J Oreopoulos, CM Yip, JT Rutka, WCW Chan Nano letters 8 (11), 3887-3892, 2008 | 157 | 2008 |
| Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy H Yuan, W Jiang, CA Von Roemeling, Y Qie, X Liu, Y Chen, Y Wang, ... Nature nanotechnology 12 (8), 763-769, 2017 | 152 | 2017 |
| Immune Priming of the Tumor Microenvironment by Radiation HSM Jiang W, Chan CK, Weissman IL, Kim, BYS Trends in Cancer 2 (11), 638, 2016 | 151 | 2016 |
| Immunomodulating nanomedicine for cancer therapy Z Liu, W Jiang, J Nam, JJ Moon, BYS Kim Nano letters 18 (11), 6655-6659, 2018 | 146 | 2018 |
| How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation JPA Ioannidis, BYS Kim, A Trounson Nature biomedical engineering 2 (11), 797-809, 2018 | 141 | 2018 |
Wen JiangUniversity of Texas MD Anderson Cancer CenterDirección de correo verificada de mdanderson.org
